A carregar...
Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach
In the wake of North America’s opioid crisis, access to evidence-based treatment for opioid use disorder (OUD) is of critical importance. While buprenorphine/naloxone and methadone are currently indicated as first-line medications for the treatment of OUD, there are a proportion of individuals who d...
Na minha lista:
| Publicado no: | BMJ Case Rep |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7167423/ https://ncbi.nlm.nih.gov/pubmed/32213504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-233715 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|